Wilmington, Delaware, Transparency Market Research Inc. – , Feb. 06, 2025 (GLOBE NEWSWIRE) — The global acute agitation and aggression treatment market was valued at approximately US$ 5.0 billion in 2023. It is projected to grow at a CAGR of 4.6% from 2024 to 2034, reaching around US$ 8.2 billion by 2034. A key factor propelling market growth is the rising prevalence of agitation and aggression in healthcare settings, particularly in emergency departments and psychiatric units, driving the demand for effective treatment solutions.
The mental health crisis further fuels the need for acute agitation and aggression treatments, as heightened awareness of mental health issues has contributed to a rise in such conditions, necessitating prompt and effective interventions.
Request a Detailed PDF Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=72345
Global Acute Agitation and Aggression Treatment Market: Key Players
The majority of the market share in the acute agitation and aggressiveness therapy sector is held by a few companies. The main players in the industry are focusing on expanding their product offerings. The main tactic used by the major companies is mergers and acquisitions. Market rivals are focusing on providing high-quality services in an effort to get a competitive advantage in the sector.
The following businesses are well-known players in the global market for treatments for acute agitation and aggression:
- Eli Lilly and Company
- Pfizer, Inc.
- GlaxoSmithKline
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals LLC
- F. Hoffmann-La Roche Ltd
- Bausch Health Companies, Inc.
- Apotex, Inc.
Key Players Lead Innovation
Leading pharmaceutical companies such as Pfizer, Otsuka Pharmaceutical, and Johnson & Johnson are investing in non-invasive treatment options, including sublingual tablets and nasal sprays, which offer faster administration and ease of use in emergency settings.
Who Are the Key Users and What Do They Need?
The primary users of treatments for acute agitation and aggression include hospitals, psychiatric clinics, and emergency care units. Healthcare professionals in these settings prioritize rapid-acting treatments that ensure patient safety and improve outcomes. These users demand therapies that can be administered quickly, with minimal side effects, to de-escalate situations effectively.
Key Findings of the Market Report
- Expanded Settings: Demand is growing beyond traditional healthcare environments, including home care, long-term care facilities, and community-based services.
- Global Market Growth: Rising awareness is driving global adoption, extending market growth beyond specific regions.
- Integrated Care Models: Collaborative care involving mental health professionals, emergency departments, social services, and law enforcement presents opportunities for holistic care solutions.
- Improved Treatment Adherence: Developing therapies with better adherence rates is expected to unlock lucrative market opportunities.
Get Customized Insights & Analysis for Your Business Needs: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=72345
Key Growth Drivers
The increase in mental health issues such as bipolar disorder, schizophrenia, and dementia has escalated the need for rapid and effective treatments for acute agitation and aggression.
Key drivers behind the market’s growth include:
- Growing Mental Health Awareness: An increasing focus on mental health by governments and healthcare organizations has led to higher diagnosis rates, further driving the demand for acute agitation treatments.
- Pharmaceutical Innovations: Major players in the industry are investing in innovative formulations, such as rapid-onset intramuscular injections and novel antipsychotic therapies that provide quicker symptom relief.
- Aging Population: As the global population ages, the prevalence of neurological disorders like dementia is increasing, leading to a rise in cases of aggression and agitation, fueling market growth.
Key Insights:
- The hospital segment is expected to dominate the market, accounting for over 50% of revenue by 2035.
- The Asia-Pacific region is witnessing significant growth, driven by rising mental health awareness and increasing investments in healthcare infrastructure in countries such as India and China.
- Non-invasive treatment options are projected to gain momentum, driven by patient preference for quick and pain-free solutions in managing acute agitation episodes.
Global Acute Agitation and Aggression Treatment Market Segmentation
- Treatment Approach
- First-Generation Anti-Psychotics
- Chlorpromazine
- Haloperidol
- Second-Generation Anti-Psychotics
- Quetiapine
- Olanzapine
- Ziprasidone
- Benzodiazepines
- Alpha-2 Adrenergic Agonist
- Others (Droperidol, etc.)
- First-Generation Anti-Psychotics
- Indication
- Alcohol Withdrawal
- Bipolar Disorder
- Dementia
- Depression
- Drug-induced agitation and aggression
- Schizophrenia
- Others (Traumatic Brain Injury, Anxiety Disorders, etc.)
- Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Key Questions Addressed:
- What are the key growth opportunities in the acute agitation and aggression treatment market?
- Which new treatment innovations are gaining traction?
- How are regional dynamics shifting in the global market?
- Who are the key players driving market growth, and what are their strategies?
Purchase the Full Market Report Today: https://www.transparencymarketresearch.com/checkout.php?rep_id=72345<ype=S
Report Highlights:
- Comprehensive Market Data: Independent analysis of annual sales, market share, and revenue projections in USD Million from 2024 to 2034.
- Regional Insights: In-depth analysis of regions including North America, Europe, Asia-Pacific, and Latin America.
- Company Profiles: Detailed profiles of leading industry players such as Pfizer, Otsuka Pharmaceutical, Johnson & Johnson, and H. Lundbeck A/S.
Explore Latest Research Reports by Transparency Market Research:
- Hydroxyapatite Market – (Hydroxylapatit-Markt) is projected to grow at a CAGR of 6.0% from 2024 to 2034 and reach more than US$ 4.4 Billion by the end of 2034.
- HIV Drugs Market – (Markt für HIV-Medikamente) is expected to grow at a CAGR of 4.7% from 2024 to 2034 and reach US$ 47.5 Billion by the end of 2034.
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn| Twitter| Blog | YouTube
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
